HOUSTON, Jan. 5, 2018 /PRNewswire/ -- RadiaDyne® announces issuance of US Patent 9,833,637, a skin patch dosimeter, whichrelates to the monitoring of skin radiation dose delivered during cancer treatment. "This issuance of this patent provides broad protection for our unique sensor delivery devices for skin applications related to the OARtrac patient radiation dose monitoring
ABOUT THE OARTRAC PLATFORM. OARtrac® is the first of its kind patient dose monitoring platform which provides gold standard accuracy, real-time pinpoint measurement, and proprietary intracavitary delivery devices to measure physical dose during radiation treatment. OARtrac® provides critical radiation dose feedback which helps facilitate adaptive radiotherapy with the goal to reduce side effects and offer better clinical outcomes.
ABOUT RADIADYNE: RadiaDyne® is a privately held diagnostic and medical device company focused on patient dose monitoring technology to improve cancer treatment outcomes. RadiaDyne designs and innovates specialized sensor technology and medical treatment devices which assist Radiation Oncologists in delivering radiation dose to the cancerous targets, while minimizing damage to the surrounding healthy tissue.
View original content:http://www.prnewswire.com/news-releases/radiadyne-receives-skin-device-patent-for-the-oartrac-patient-radiation-dose-monitoring-system-300578305.html
Subscribe to our Free Newsletters!
The Hib vaccine protects children against infections like meningitis and pneumonia that are caused ...
Dysthymia or persistent depressive disorder (PDD) is a chronic low mood and self-esteem affecting ...
Vitamin A is an extremely vital vitamin needed for the eyes, skin, hair, immunity and during ...View All